Press Releases Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 10/07/2026 +04			5-day change	1st Jan Change
76.23 ^EUR	-0.33%		+0.55%	-7.85%

07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT

Press Releases

07-10	Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector	GL
07-09	Europa-Commission seeks feedback on commitments offered by Sanofi over possible anticompetitive conduct regarding the promotion of a flu vaccine for vulnerable patients	AQ
07-04	European Comission - Commission Opens Investigation Into Sanofi Over Alleged Disparagement Of Rival Flu Vaccine	AQ
07-01	Availability of the aide-mémoire for Q2 2026 results	GL
06-30	Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study	GL
06-29	Europa-Commission opens investigation into possible anticompetitive conduct by Sanofi regarding the promotion of a flu vaccine for vulnerable patients	AQ
06-25	Sanofi Foundation opens new chapter centered on future generations	GL
06-23	DoH and Sanofi Partner to Advance Vaccine Innovation	AQ
06-23	Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia	GL
06-23	Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses	GL
06-22	Sanofi appoints Paulo Fontoura as Global Head of R&D	GL
06-19	Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma	GL
06-18	QuantHealth Expands Executive Team with World-Class Medical and Innovation Leaders	AQ
06-13	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	GL
06-10	Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy	GL
06-08	Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector	GL
06-04	Sanofi federates the healthcare ecosystem to accelerate the diagnosis of rare diseases in France, Biogen joins accelRare	AQ
06-04	Sanofi launches 2026 global employee stock purchase plan	GL
06-02	UPC Turns Three: Statistics, Milestones, And Trends	AQ
05-29	Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease	AQ
05-28	Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease	GL
05-18	ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD	GL
04-29	Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi	GL
04-27	Sanofi's Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses	AQ
04-24	Sanofi successfully prices 2.3 billion of bond issue	GL